Master thesis: Aggregation mechanisms of proteins in liquid formulations - Hiring in process/Finished, not possible to apply

Do you want to contribute to deepening the knowledge within the development of biological pharmaceuticals? Would you like to work in an innovative-driven environment with experts in formulations for pharmaceuticals, medtech, foods, and cosmetics? We are now seeking a master’s thesis student interested in biological pharmaceuticals to explore the physical stability of therapeutic proteins in liquid formulations.

Background
Biological pharmaceuticals are a growing segment of new drugs reaching the market. They have many benefits over small molecule drugs, such as higher specificity and lower toxicity. However, some challenges still need to be studied further to develop stable, safe, and effective drugs. Aggregation and particle formation in liquid formulations affect the long-term stability and can cause issues with loss of efficacy and immunogenicity. In this project, you will work with therapeutic proteins and study the mechanism behind aggregation and particle formation.

Goal
To evaluate how non-native proteins act as seeding points for aggregation in the bulk solution. The study will consider thermal stability, size distribution, and concentration using techniques like micro-DSC, DLS, UV-Vis. AF4 and miniTEM might be used as complementary techniques.

Requirements/Knowledge
For this diploma work, the student should be enrolled in a master's program in pharmacy, biotechnology/chemical engineering, or similar, and preferably have background knowledge on protein structure and drug formulation.

Terms
Project period: Spring term 2022, 30 hp. Start upon agreement.
Placement: RISE, Malvinas väg 3, Stockholm

Welcome with your application!
For questions and more information, please contact Amanda Västberg, +46 10 516 59 85.

The last day for application is 7 November 2021. Interviews with candidates will be conducted continuously, and acceptance can be made at any point.

Master thesis, formulation, therapeutic proteins, RISE, Stockholm